NEWS
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown Convention Center in Houston, TX.
The presentation, titled 'Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors', is scheduled for Friday, November 8, 2024, at 9:00a CDT in Exhibit Halls AB. The presentation materials will be available on the 'Publication' section of BioAtla's website after the presentation concludes.
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown Convention Center in Houston, TX.
The presentation, titled 'Updated results from a phase 1 study of evalstotug (BA3071), an anti-CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors', is scheduled for Friday, November 8, 2024, at 9:00a CDT in Exhibit Halls AB. The presentation materials will be available on the 'Publication' section of BioAtla's website after the presentation concludes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2327Followers
106Following
24KVisitors
Follow